BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kondo M, Morimoto M, Ishii T, Nozaki A, Fukuda H, Numata K, Kobayashi S, Ohkawa S, Hidaka H, Nakazawa T, Shibuya A, Okuse C, Suzuki M, Sakamaki K, Morita S, Maeda S, Tanaka K. Hepatic arterial infusion chemotherapy with cisplatin and sorafenib in hepatocellular carcinoma patients unresponsive to transarterial chemoembolization: a propensity score-based weighting. J Dig Dis 2015;16:143-51. [PMID: 25495751 DOI: 10.1111/1751-2980.12221] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Ni JY, Liu SS, Sun HL, Wang WD, Zhong ZL, Hou SN, Chen YT, Xu LF. Transcatheter hepatic arterial infusion chemotherapy vs sorafenib in the treatment of patients with hepatocellular carcinoma of Barcelona Clinic Liver Cancer stage C: a meta-analysis of Asian population. Onco Targets Ther 2018;11:7883-94. [PMID: 30464535 DOI: 10.2147/OTT.S156844] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
2 Lee S, Kang JH, Kim DY, Ahn SH, Park JY, Kim BK, Kim SU, Han KH. Prognostic factors of sorafenib therapy in hepatocellular carcinoma patients with failure of transarterial chemoembolization. Hepatol Int. 2017;11:292-299. [PMID: 28324324 DOI: 10.1007/s12072-017-9792-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
3 Fu J, Wang Y, Zhang J, Yuan K, Yan J, Yuan B, Guan Y, Wang M. The safety and efficacy of transarterial chemoembolisation with bleomycin for hepatocellular carcinoma unresponsive to doxorubicin: a prospective single-centre study. Clin Radiol 2021;76:864.e7-864.e12. [PMID: 34452734 DOI: 10.1016/j.crad.2021.07.013] [Reference Citation Analysis]
4 Yoo SH, Kwon JH, Nam SW, Lee JY, Kim YW, Shim DJ, Lee SW, Jang JW. Transarterial Infusion of Epirubicin and Cisplatin Combined With Systemic Infusion of 5-Flurouracil Versus Sorafenib for Hepatocellular Carcinoma With Refractoriness of Transarterial Chemoembolization Using Doxorubicin. Cancer Control 2020;27:1073274820935843. [PMID: 32583687 DOI: 10.1177/1073274820935843] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Zhuang BW, Li W, Xie XH, Hu HT, Lu MD, Xie XY. Sorafenib versus hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis. Jpn J Clin Oncol 2019;49:845-55. [PMID: 31063184 DOI: 10.1093/jjco/hyz069] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
6 Maeda H, Miura K, Morimoto N, Watanabe S, Tsukui M, Takaoka Y, Nomoto H, Goka R, Sato N, Morishima K, Sakuma Y, Sata N, Fukushima N, Isoda N, Yamamoto H. Conventional Therapies Do Not Prolong the Prognosis of Hepatocellular Carcinoma Patients with Extrahepatic Metastases under Receiving of Tyrosine Kinase Inhibitors. Cancers (Basel) 2022;14:752. [PMID: 35159018 DOI: 10.3390/cancers14030752] [Reference Citation Analysis]
7 Yin S, Chen X, Xie H, Zhou L, Guo D, Xu Y, Wu L, Zheng S. Nanosecond pulsed electric field (nsPEF) enhance cytotoxicity of cisplatin to hepatocellular cells by microdomain disruption on plasma membrane. Exp Cell Res 2016;346:233-40. [PMID: 27375200 DOI: 10.1016/j.yexcr.2016.06.018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
8 Ohki T, Sato K, Yamagami M, Ito D, Yamada T, Kawanishi K, Kojima K, Seki M, Toda N, Tagawa K. Efficacy of transcatheter arterial chemoembolization followed by sorafenib for intermediate/advanced hepatocellular carcinoma in patients in Japan: a retrospective analysis. Clin Drug Investig 2015;35:751-9. [PMID: 26446004 DOI: 10.1007/s40261-015-0333-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
9 Moriya K, Namisaki T, Takaya H, Kaji K, Kawaratani H, Shimozato N, Sawada Y, Douhara A, Sato S, Furukawa M, Kitagawa K, Akahane T, Yoshiji H. Identification of the Response-Related Biomarker of Bimonthly Hepatic Arterial Infusion Chemotherapy. J Clin Med 2021;10:629. [PMID: 33562238 DOI: 10.3390/jcm10040629] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]